Careers: Winning with people
Our employees are the foundation of our innovative strength. We continue to put people first in everything we do and support our employees in the key moments of their careers.
Search
Shared science for the best cat diabetes management
Diabetes mellitus is a common endocrine disease with increasing prevalence in dogs and cats. Learn how science's made management easier.
Boehringer Ingelheim reaches more patients than ever, innovation drives growth
Boehringer Ingelheim reports a strong performance in 2022.
Striving to revolutionize mental health research
World Mental Health Day: Through a precision psychiatry approach and rich pipeline, we are committed to transforming the mental health landscape.
2018 Animal Welfare Medals
2018 Animal Welfare Medals: Boehringer Ingelheim recognizes outstanding research in cattle, equine, swine, as well as small animals and pet categories
Respimat re-usable wins Pharmapack Eco-Design Award
The Respimat® re-usable inhaler device has won the 2020 Pharmapack Eco-Design Award. An enhanced version of the Respimat® soft mist inhaler, Respimat® re-usable has a lower environmental impact and is easy for patients to use.
Partnership to further develop pet market in China
Boehringer Ingelheim invests in partnership to further develop the pet market in China, acquires a stake in New Ruipeng Group
Collaborating for social impact
Societal challenges require collective action and Making More Health Together is connecting changemakers to drive collaborations for more social impact
On the road with sanitation workers in India
Exhaust fumes, heat, work and traffic accidents. Overcoming all these odds, the sanitation workers in India fight a daily battle.
Positive-CHMP-opinion-for-dabigatran-in-children
Positive CHMP opinion received for use of dabigatran for the treatment and prevention of venous thromboembolic events in children
cystic fibrosis phase II trial
The first patient has been enrolled in a phase II trial to evaluate an innovative treatment for cystic fibrosis, inhaled via the Respimat® inhaler
All hands-on deck to fight the ‘zombie’ rabies virus
We’re teaming up with communities and governments across Southeast Asia to fight rabies through vaccinations, education programs, and partnerships.
New Therapeutic Antibody Discovery Collaboration
Proprietary antibody libraries to help discover therapeutic antibodies against multiple targets
Boehringer Ingelheim: Discover the app set to transform animal care in rural India
Learn about the app set to transform animal care in rural India. Women will be empowered and goat welfare will be promoted. From idea to app!
Could decentralised trials transform the way we view depression?
Could decentralised trials transform the way we view depression? Dr Vikas Mohan Sharma believes this could deliver meaningful changes for patients all arround.
The chronic nature of generalized pustular psoriasis
Understanding the impact of the physical and psychological symptoms of this chronic disease.
Social Media Data Privacy and Cookies Statement
CARMELINA-elderly-analysis
CARMELINA® outcome trial subgroup analysis demonstrates long-term cardiovascular and renal safety data in older people with type 2 diabetes
Discover your hidden talent with BI Open – the new platform for data science enthusiasts
Discover your hidden talent with BI Open – the new platform for data science enthusiasts. For more talent insights, visit our Careers Page.
Imagine: The impact of volunteering activities on elderly well-being
How our employees contribute to elderly well-being with creative volunteering activities in Australia, South Korea, Southeast Asia, and New Zealand.
New digital Tx collab with Click
New digital therapy collaboration with Click Tx
The impact of carbon reduction projects
Boehringer Ingelheim voluntarily contributes to carbon reduction projects that benefit sustainable development.
View from Both Sides of the Table
Scott DeWire, US Head of BD&L shares experiences that have taught him first-hand the foundations of successful partnerships
International Postdocs realize their potential in Biberach
Three talented postdocs report on what they are working at Boehringer Ingelheim's research site in Biberach and what attracts them to the company.
Targeting HER2 in cancer: The story of zongertinib
We discovered zongertinib, an HER2 tyrosine kinase inhibitor, being developed as a potential oral treatment for people with HER2-mutated NSCLC